Predicate |
Object |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-1093 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/H04L25-03063 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6811 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6851 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-1045 |
classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/H04L25-03 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-55 |
filingDate |
2004-02-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7f765d15247eeb3ddf7f9ea6237db9c3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_68f1735ce689fc2f05a5d4c325a58c4f |
publicationDate |
2004-08-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-2004156824-A1 |
titleOfInvention |
Vasopermeability enhancing peptide of human interleukin-2 and immunoconjugates thereof |
abstract |
A novel permeability enhancing peptide (PEP) is a fragment of interleukin-2. When joined to a delivery vehicle that can target a tumor site, the PEP can increase the subsequent uptake of antineoplastic or tumor imaging agents. The PEP can be chemically joined to a monoclonal antibody to form an immunoconjugate. Alternatively, an expression vector is genetically engineered to express a fusion protein. The fusion protein has an antigen-binding portion joined to the PEP. The PEP is most effective when it takes the form of a dimer, linked by a disulfide bridge. The PEP is substantially free of cytokine activity and produces minimal toxic side effects on normal tissues. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2010003268-A3 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2010003268-A2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/SG-122897-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011135644-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2769711-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8697074-B2 |
priorityDate |
1996-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |